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Context. At present, there is no widely used systematic evidence-based holistic approach to assessment of patients’
supportive and palliative care needs.
Objectives. To determine whether the use of a holistic needs assessment questionnaire, Sheffield Profile for Assessment
and Referral for Care (SPARC), will lead to improved health care outcomes for patients referred to a palliative care service.
Methods. This was an open, pragmatic, randomized controlled trial. Patients (n¼ 182) referred to the palliative care service
were randomized to receive SPARC at baseline (n ¼ 87) or after a period of two weeks (waiting-list control n ¼ 95). Primary
outcome measure is the difference in score between Measure Yourself Concerns and Wellbeing (MYCAW) patient-nominated
Concern 1 on the patient self-scoring visual analogue scale at baseline and the two-week follow-up. Secondary outcomes include
difference in scores in the MYCAW, EuroQoL (EQ-5D), and Patient Enablement Instrument (PEI) scores at Weeks 2, 4, and 6.
Results. There was a significant association between change in MYCAW score and whether the patients were in the
intervention or control group (c2trend ¼ 5.51; degrees of freedom ¼ 1; P ¼ 0.019). A higher proportion of patients in the
control group had an improvement in MYCAW score from baseline to Week 2: control (34 of 70 [48.6%]) vs. intervention (19
of 66 [28.8%]). There were no significant differences (no detectable effect) between the control and intervention groups in
the scores for EQ-5D and Patient Enablement Instrument at 2-, 4-, or 6-week follow-up.
Conclusion. This trial result identifies a potential negative effect of SPARC in specialist palliative care services, raising
questions that standardized holistic needs assessment questionnaires may be counterproductive if not integrated with a
clinical assessment that informs the care plan. J Pain Symptom Manage 2015;50:587e598.  2015 The Authors. Published by
Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Key Words
Palliative care, holistic needs assessment questionnaire, SPARC, MYCAW, EQ-5D, PEI
disease. SPARC is intended for use by primary care,Introduction
The Sheffield Profile for Assessment and Referral
for Care (SPARC) (Appendix I, available at
jpsmjournal.com) is a multidimensional holistic needs
assessment questionnaire, designed to identify pa-
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Table 1
Follow-Up Procedure
Questionnaire Completion
(at 2-week intervals)
Randomization
Group A (Intervention Group) Group B (Waiting-List Control Group)
Baseline MYCAW, EQ-5D, PEI, SPARC MYCAW, EQ-5D, PEI
Two weeks MYCAW, EQ-5D, PEI
[Invitation for patient interview]
MYCAW, EQ-5D, PEI, SPARC
Four weeks MYCAW, EQ-5D, PEI plus supplementary question
on experience of completing the SPARC
MYCAW, EQ-5D, PEI
[Invitation for patient interview]
Six weeks MYCAW, EQ-5D, PEI MYCAW, EQ-5D, PEI plus supplementary question
on experience of completing the SPARC
Eight weeks Case note reviews
Semistructured interviews with patients
Semistructured interviews with health care professionals
MYCAW ¼Measure Yourself Concerns and Wellbeing; EuroQoL (EQ-5D) ¼ standardized outcome measure of health-related quality of life; PEI ¼ Patient Enable-
ment Instrument; SPARC ¼ Sheffield Profile for Assessment and Referral for Care.
Those patients who consented were randomized to receive the SPARC questionnaire at baseline (intervention group) or after a two-week waiting-list period
(control group).
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tients unassisted, or, for those prevented by disability
from reading or writing responses, with the help of
their informal or professional carers.2 Despite
rigorous psychometric development, preliminary field
testing, and validation,1e6 the clinical utility of SPARC
has yet to be established, either as an aid to specialist
clinical assessment or as a screening tool.7
There is evidence to suggest that patients with cancer
and nonmalignant chronic progressive illnesses may
experience distressing symptoms and concerns, which
may remain unrecognized.7e10 Previous research has
highlighted that distressing symptoms and concerns
can be managed, provided they are identified in a
timely manner and systems are in place for a prompt
referral to specialist teams.11e16 The timely identifica-
tion of needs and prompt referral to specialist teams
could reduce the burden of suffering and lead to
earlier discharge. Similarly, earlier detection of these
problems in outpatients or the community might pre-
vent unnecessary admissions. These potential health
gains may accrue for a relatively small investment.7
However, at present, there is no widely used systematic
evidence-based holistic approach to assessing patients
for supportive and palliative care needs. There is a
lack of studies on the clinical utility of tools.1,7
We conducted a pilot pragmatic randomized
controlled trial to determine whether the use of
SPARC leads to improved health care outcomes
(health-related quality of life and self-identified con-
cerns) for patients referred to a palliative care service,
to guide the development of a definitive multicenter
study. This study represents a development of SPARC
for use as an early holistic needs assessment question-
naire within a specialist service. This study does not
test the utility of SPARC as a screening questionnaire
for specialist palliative care. Palliative care interven-
tions are complex, and in light of this, the SPARC
study was developed, piloted, evaluated, reported,and implemented in accordance with the Medical
Research Council framework for developing and eval-
uating complex interventions (new guidance).17e19Methods
Trial Design and Recruitment
The trial is reported in accordance with the Con-
solidated Standards of Reporting Trials (CONSORT)
2010 statement20 and was registered (International
Standard Randomised Controlled Trials Number
[ISRCTN] 25758268). This open randomized
controlled trial used a waiting-list control design.21
All patients referred to the supportive and palliative
care service who met the study inclusion criteria
were invited to take part in the study. Invitations to
participate were sent by post (outpatients and those
in the community) or given face to face (inpatients
and day care patients). Patients who consented to tak-
ing part in the study were randomized to receive the
SPARC questionnaire at baseline (intervention group)
or after a two-week period (control group).
The study received approval from the Bradford
Research Ethics Committee, U.K. Multicentre Research
Ethics Committee (MREC) reference number 10/
H1302/88 on January 14, 2011 and received research
and development permission from local trusts. Partici-
pants’ inclusion criteria were 1) any diagnosis (cancer
and noncancer), 2) any referral to the palliative care ser-
vice in any care setting, 3) 18 years or older, and 4) able
to give informed consent. Exclusion criteria included 1)
incapable of giving informed consent, 2) incapable of
completing SPARC even with the help of a relative or
informal carer, and 3) younger than 18 years.
Stratification
Baseline quality of life may confound response to an
intervention by reversion to the mean, so patients
Table 2
Research Questionnaires: Rationale for Choice of Outcome Measures
MYMOP
MYCAW
Slightly Modified Version
of MYCAW Used EQ-5D
PEI
Slightly Modified Version
of PEI Used
- A precursor of MYCAW
- Demonstrated sensitivity to
change
- Used in a range of contexts
- Patient self-complete, outcome
questionnaire, problem
specific (includes general well-
being)
- Applicable to all symptomatic
patients
- Brief and simple questionnaire
to administer
- MYCAW used in preference to
MYMOP because concerns
raised could be of any kind and
not restricted to symptoms or
activity (may be of significance
when comparing the
information from the three
groups: cancer survivors,
people with long-term
conditions, and people
needing end-of-life care)
- For the purposes of this study,
it was important to use an
outcome measure that covered
the diversity in the patient
group
- A slightly modified version of
MYCAW was used (the sentence
‘‘Please write down one or two
concerns or problems which you
would most like us to help you
with’’ was replaced with ‘‘Please
write down one or two concerns or
problems that bother you most’’)
References: 24e26
- Developed from a validated
tool, MYMOP, simple to use,
and sensitive enough to show
any changes with time
- Patients nominate concerns,
which may or may not be
medical (MYCAW) or
symptoms (MYMOP) of
importance to them (two
concerns/symptoms can be
identified)
- They then score these on a
scale of 0 (not bothering me at
all) to 6 (bothers me greatly)
- Patients are also asked to rate
their general feeling of well-
being on a scale of 0 (as good
as it could be) to 6 (as bad as it
could be)
- The follow-up form asks
patients to rescore the
concerns/symptoms and rate
their general feeling of well-
being they previously
nominated, thus capturing any
changes over time that are
important to the patient
- However, HRQoL may not be
sensitive enough to changes in
the short term, possibly
because people adjust their
expectations
- Work by Guyatt et al.27
indicates that in seven-point
scales of this kind, a shift of one
point corresponds to a
moderately important change
for a patient
- Is an additional element of
needs assessment, stated
concerns, are truly patient
generated, reflecting an
accurate expression of need at
that time
References: 25e27
- Outcome measure of health-
related quality of life
- Patient self-complete
- Five questions (three varying
response categories): on
mobility, self-care, usual
activities (e.g., work, study,
housework, family, or leisure
activities), pain/discomfort,
and anxiety/depression
- A further question (EQ-5D
thermometer scale) asks
people to mark their current
health status on a scale of
0 (worst imaginable health
state) to 100 (best imaginable
health state)
- Used extensively in studies
where quality of life is
compared between patient
groups
References: 23,28
- Outcome measure of a
patient’s ability to cope with
life and their illness and the
confidence and ability to help
themselves (as a result of
visiting a doctor or health
professional)
- Patient self-complete
- One main question ‘‘thinking
about the last time you saw a
doctor or nurse from palliative
care, do you feel you are: .
(6 subquestions with four
varying response categories)
- Studies in general practice to
assess quality of consultations
using PEI have shown it to be a
crucial outcome measure, with
enablement correlating best
with the length of consultation
and how well the patient knew
the doctor
- PEI scores consultations in
cancer clinics, independently
of quality of life and scores
higher when sufficient time is
allocated or when staff have
communication skills training
(our own unpublished work)
- PEI may detect an effect of
SPARC (if any) on the quality
of subsequent consultations
with the clinical team
- A measure of consultation
quality was included to detect
an effect on communication
between patients and
professionals. However, we
overestimated the intensity of
contact between patients and
professionals and palliative
care services in the duration of
this trial
References: 29,30
MYMOP ¼ Measure Yourself Medical Outcomes Profile; MYCAW ¼ Measure Yourself Concerns and Wellbeing; EuroQoL (EQ-5D) ¼ standardized outcome mea-
sure of health-related quality of life; PEI ¼ Patient Enablement Instrument; HRQoL ¼ health-related quality of life.
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outcome measure of health-related quality of life)
thermometer score. Thus, patients completing the
consent form also were asked to complete the EQ-
5D thermometer score before randomization. Based
on previous work,22,23 the research team set the EQ-
5D thermometer score at 40. Patients scoring 40 or
above at baseline were placed in the median and
above group, and those scoring less than 40 were
placed in the below median group.
Sheffield Palliative Care Service Context and Settings
Patients were recruited from the whole range of set-
tings (inpatients, outpatients, day care, and from thecommunity), which included the two hospitals within
the city, a palliative care unit, a hospice, and from
the community via a team of community specialist
nurses. More than 2000 patients a year are referred
to these services, including those with long-term con-
ditions and cancer survivors as well as those needing
end-of-life care.
Intervention (SPARC)
Those patients who consented were randomized to
receive the SPARC questionnaire (Table 1) at base-
line (intervention group) or after a two-week wait-
ing-list period (control group). All patients received
ongoing care as usual. A completed paper copy of
SPARC at baseline or SPARC at week 2 
Fig. 1. Summary of recruitment for the Sheffield Profile for Assessment and Referral for Care (SPARC) trial. There was no
significant difference in the number of deaths between the intervention and control groups. In Group A (intervention),
nine people (10.3%) died within the eight-week study period and in Group B (control), 14 people (14.7%) died within
the eight-week study period (c2 ¼ 0.445; degrees of freedom ¼ 1; P ¼ 0.504).
590 Vol. 50 No. 5 November 2015Ahmed et al.SPARC was sent to the health care professional
(HCP) caring for the patient to prompt action on
needs identified by SPARC. The SPARC question-
naire data also were kept in the patients’ notes, and
a copy was kept on the electronic clinical record.
Follow-up study questionnaires were administered
either face to face or by post. Two weeks was selected
as the crucial follow-up time after baseline to mini-
mize attrition.
Outcome Measures
Study participants were required to complete
three validated brief self-complete research outcome
measures: the Measure Yourself Concerns and
Wellbeing (MYCAW), the EuroQoL (EQ-5D) (mea-
sure of health-related quality of life), and the Patient
Enablement Instrument (PEI) at baseline, Week 2,
Week 4, and Week 6 (Appendix II, available at
jpsmjournal.com). The rationale for the choice of
outcome measures is presented in Table 2.24e30
The primary outcome was the change in MYCAW
score between the first MYCAW patient-nominated
concern at baseline and the two-week follow-up.
This is the nominated first concern. Secondary out-
comes included 1) the change in scores in the EQ-
5D at the two time points; 2) changes in the PEI at
the two time points; 3) comparisons of MYCAW
patient-nominated concerns, EQ-5D, and the PEI at
baseline between patient groups; and 4) the pattern
of actions taken and referrals made as a result of
administering the SPARC screening tool wereexamined by analysis of the clinical record (to be re-
ported elsewhere).
Randomization
A set of sequentially numbered, opaque, sealed, A4
envelopes containing all study documents were set up
for each care setting (henceforth called the study
pack). The randomization process was undertaken
by a member of the study team (M.W.), who then iden-
tified which study packs were for the intervention arm
and which were for the control arm. A copy of the
SPARC questionnaire (Appendix I) was added to the
study packs for the intervention arm, and 182 patients
were randomized with computer-generated random
numbers in prepaid sealed envelopes to receive
SPARC at baseline (n ¼ 87) or after a period of two
weeks (waiting-list control n ¼ 95).
Recruitment
For inpatients and day care patients, a HCP
informed the patients about the study and asked
whether they were willing to participate. Contact de-
tails of those patients willing to participate were
passed to a member of the study team. Community
patients and outpatients were sent study packs via
medical secretaries (the list of patients was first
agreed with the HCP with responsibility for the
care of these patients). On receiving consent, the
researcher (N.A.), who was blinded to the study,
collected the next sequentially numbered, opaque,
sealed envelope and hand delivered it to inpatients
Table 3
Baseline Demographic Characteristics of Participants in Group A (Intervention), Group B (Control), and otal Sample (A D B)
Characteristic
Intervention Group A (87) Control Group B (95) All Patients (182) Notes A vs. B
n (%) P
Age (mean age in yrs) on
registration
63.90 years (median ¼ 65.00 years;
SD ¼ 11.68; minimum
age ¼ 28 years; maximum
age ¼ 87 years)
64.99 years (median ¼ 67.00 years;
SD ¼ 13.34; minimum
age ¼ 27 years; maximum
age ¼ 90 years)
64.47 years (median ¼ 66.0 years;
SD ¼ 12.57; minimum
age ¼ 27 years; maximum
age ¼ 90 years)
No significant difference (Mann-
Whitney Z ¼ 0.865; P ¼ 0.387)
Gender No significant difference (c2 ¼
1.183; degrees of freedom ¼ 1;
P ¼ 0.277)
Male 36 (41.4) 48 (50.5) 84 (46.2)
Female 51 (58.6) 47 (49.5) 98 (53.8)
Partnership/marital status No significant difference (c2 ¼
1.706; degrees of freedom ¼ 3;
P ¼ 0.636). Most patients were
married (n ¼ 118; 64.8%)
Married 56 (64.4) 62 (65.3) 118 (64.8)
Single 10 (11.5) 7 (7.4) 17 (9.3)
Divorced/parted/separated 5 (5.7) 9 (9.5) 14 (7.7)
Widowed 15 (17.2) 15 (15.8) 30 (16.5)
Ethnicity
WhitedBritish 83 (95.4) 90 (94.7) 173 (95.1) The low numbers in many of the
groups meant that it was not
possible to test for differences
Whitedother background 2 (2.3) 0 (0) 2 (1.1)
Black or Black British
Caribbean
1 (1.1) 0 (0) 1 (0.5)
Asian or Asian British-Indian 0 (0) 1 (1.1) 1 (0.5)
Information withheld/not
documented
1 (1.1) 4 (4.2) 5 (2.7)
Living arrangements Most patients were living at home
(n ¼ 177; 97.3%), three patients
were living in a care or nursing
home (1.6%), and for two
patients (1.1%) it was not known
where they were living
Home 83 (95.4) 94 (98.9) 177 (97.3)
Care home/nursing home 3 (3.4) 0 (0) 3 (1.6)
Patient lives alone No significant difference in the
proportions of patients living
alone (c2 ¼ 0.020; degrees of
freedom ¼ 1; P ¼ 0.887)
Living alone 15/73 (20.5) 20/88 (22.7) 35 (19.2)
Religion Most patients (n ¼ 115; 63.2%) gave
their religious denomination as
Church of England
Church of England 56 (64.4) 59 (62.1) 115 (63.2)
Roman Catholic 6 (6.9) 5 (5.3) 11 (6.0)
Christian 5 (5.7) 7 (7.4) 12 (6.6)
Jewish 2 (2.3) 2 (2.1) 4 (2.2)
Methodist 3 (3.4) 4 (4.2) 7 (3.8)
Protestant 1 (1.1) 1 (1.1) 2 (1.1)
Humanist 1 (1.1) 0 (0) 1 (0.5)
Anglican 1 (1.1) 0 (0) 1 (0.5)
Agnostic 0 (0) 2 (2.1) 2 (1.1)
Quaker 1 (1.1) 2 (2.1) 3 (1.6)
Church of Scotland 1 (1.1) 0 (0) 1 (0.5)
None 10 (11.5) 13 (13.7) 23 (12.6)
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outpatients.
Statistical Methods and Analysis
Primary Endpoint Analysis. The primary outcome
measure was the difference in score between the
patient-nominated concern (MYCAW, Concern 1) on
the self-scored visual analogue scale at baseline and
at the two-week follow-up. Assuming the changes in
the score (baseline to Week 2) would be normally
distributed, we had planned to carry out a t-test to
test the null hypothesis that the difference between
the intervention and control groups in the mean score
on the first symptom nominated on the scale at base-
line and two weeks is 0. However, because the data
were not normally distributed, the Mann-Whitney
test was used to test for difference in the two groups
in the rankings of Weeks 2, 4, and 6 scores and the
rankings of the change in scores from baseline to
Weeks 2, 4, and 6.
Statistical Power. To detect a medium-sized difference
between two independent sample means at alpha ¼
0.05andbeta¼ 0.80, requiredaminimumof64 individ-
uals in each group with scores at baseline and two
weeks.31 Therefore, a total of 128 patients would need
to be recruited. The power of the study was based on
the randomized controlled trial with the group of pa-
tients from whom it would be possible to obtain
follow-up data. Differences between the control and
interventiongroupswere testedusing t-tests tocompare
the mean scores at Weeks 2, 4, 6, and the mean change
in scores from baseline to Weeks 2, 4, and 6.
Secondary and Exploratory Analyses. Statistical analysis
of the comparisons between patient groups for the
secondary outcomes involved both descriptive ana-
lyses and statistical tests. A qualitative content anal-
ysis32,33 of the nominated first concern and the
nominated second concern was undertaken at base-
line. The concerns named in MYCAW were analyzed
qualitatively using a summative content analysis
approach. Stated concerns were examined for key
words and themes, with the context taken into ac-
count for the final interpretation. Analysis of the
data from patient semistructured interviews, HCP in-
terviews,34 case note reviews, and from the supple-
mentary question about patients’ experience of
completing the SPARC will be presented elsewhere.D
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Recruitment and Attrition Rates
A total of 850 patients were invited to take part in
the study, of whom 225 consented to take part
Table 5
Frequency of EQ-5D Responses in Groups A (Intervention) and B (Control) and Total Sample (A D B) at Bas ine and Weeks 2, 4, and 6
Domain Statement
Baseline
Response, n (%)
Week 2
Response, n (%)
Week
Response, (%)
Week 6
Response, n (%)
Group A B Total A B Total A B Total A B Total
Mobility I have no problems in walking
about
13 (15.7) 9 (9.5) 22 (12.4) 11 (15.1) 10 (13.0) 21 (14.0) 10 (16.9) 8 (12. 18 (14.6) 8 (14.3) 5 (7.9) 13 (10.9)
I have some problems in walking
about
66 (79.5) 85 (89.5) 151 (84.8) 60 (82.2) 64 (83.1) 124 (82.7) 48 (81.4) 53 (82. 101 (82.1) 45 (80.4) 56 (88.9) 101 (55.5)
I am confined to bed 4 (4.8) 1 (1.1) 5 (2.8) 2 (2.7) 3 (3.9) 5 (3.3) 1 (1.7) 3 (4.7 4 (3.3) 3 (5.4) 2 (3.2) 5 (2.7)
Total 83 (100) 95 (100) 178 (100) 73 (100) 77 (100) 150 (100) 59 (100) 64 (100 123 (100) 56 (100) 63 (100) 119 (100)
Self-care I have no problems with self-care 43 (53.1) 43 (45.3) 86 (48.9) 37 (51.4) 36 (46.8) 73 (49.0) 34 (57.6) 28 (44. 62 (50.8) 31 (55.4) 27 (42.9) 58 (48.7)
I have some problems washing or
dressing myself
33 (40.7) 48 (50.5) 81 (46.0) 31 (43.1) 36 (46.8) 67 (45.0) 22 (37.3) 33 (52. 55 (45.1) 20 (35.7) 33 (52.4) 53 (44.5)
I am unable to wash or dress
myself
5 (6.2) 4 (4.2) 9 (5.1) 4 (95.6) 5 (6.5) 9 (6.0) 3 (5.1) 2 (3.2 5 (4.1) 5 (8.9) 3 (4.8) 8 (6.7)
Total 81 (100) 95 (100) 176 (100) 72 (100) 77 (100) 149 (100) 59 (100) 63 (100 122 (100) 56 (100) 63 (100) 119 (100)
Usual activities I have no problems with
performing my usual activities
7 (8.4) 6 (6.5) 13 (7.4) 7 (9.7) 8 (10.3) 15 (10.0) 3 (5.1) 8 (12. 11 (8.9) 4 (7.4) 7 (11.1) 11 (9.4)
I have some problems with
performing my usual activities
54 (65.1) 59 (63.4) 113 (64.2) 46 (63.9) 49 (62.8) 95 (63.3) 40 (67.8) 38 (59. 78 (63.4) 31 (57.4) 40 (63.5) 71 (60.7)
I am unable to perform my usual
activities
22 (26.5) 28 (30.1) 20 (28.4) 19 (26.4) 21 (26.9) 40 (26.7) 16 (27.1) 18 (28. 34 (27.6) 19 (35.2) 16 (25.4) 35 (29.9)
Total 83 (100) 93 (100) 176 (100) 72 (100) 78 (100) 150 (100) 59 (100) 64 (100 123 (100) 54 (100) 63 (100) 117 (100)
Pain/discomfort I have no pain or discomfort 11 (13.3) 9 (9.8) 20 (11.4) 9 (12.5) 10 (13.2) 19 (12.8) 6 (10.3) 3 (4.8 9 (7.5) 8 (14.8) 4 (6.6) 12 (10.4)
I have moderate pain or
discomfort
59 (71.1) 72 (78.3) 131 (74.9) 55 (76.4) 55 (72.4) 110 (74.3) 44 (75.9) 54 (87. 98 (81.7) 34 (63.0) 53 (86.9) 87 (75.7)
I have extreme pain or discomfort 13 (15.7) 11 (12.0) 24 (13.7) 8 (11.1) 11 (14.5) 19 (12.8) 8 (13.8) 5 (8.1 13 (10.8) 12 (22.2) 4 (6.6) 16 (13.9)
Total 83 (100) 92 (100) 175 (100) 72 (100) 76 (100) 148 (100) 58 (100) 62 (100 120 (100) 54 (100) 61 (100) 35 (29.9)
Anxiety/depression I am not anxious or depressed 34 (42.0) 29 (31.9) 63 (36.6) 31 (43.1) 23 (29.9) 54 (36.2) 23 (40.4) 18 (29. 41 (34.5) 19 (34.5) 23 (37.7) 42 (36.2)
I am moderately anxious or
depressed
42 (51.9) 55 (60.4) 97 (56.4) 37 (51.4) 52 (67.5) 89 (59.7) 31 (54.4) 41 (66. 72 (60.5) 29 (52.7) 34 (55.7) 63 (54.3)
I am extremely anxious or
depressed
5 (6.2) 7 (7.7) 12 (7.0) 4 (5.6) 2 (2.6) 6 (4.0) 3 (5.3) 3 (4.8 6 (5.0) 7 (12.7) 4 (6.6) 11 (9.5)
Total 81 (100) 91 (100) 172 (100) 72 (100) 77 (100) 149 (100) 57 (100) 62 (100 119 (100) 55 (100) 61 (100) 116 (100)
EuroQoL (EQ-5D) ¼ standardized outcome measure of health-related quality of life.
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Table 6
Distribution of PEI Responses in Groups A (Intervention) and B (Control) and Total Sample (AD B) at Baseline, Weeks 2,
4 and 6
Question Response, n (%)
Baseline Week 2
Group A
(Intervention)
Group B
(Control) Total P
Group A
(Intervention)
Group B
(Control)
Able to cope with life Much better 8 (10.0) 8 (9.0) 16 (9.5) 0.301 4 (5.8) 9 (12.7)
Better 32 (40.0) 28 (31.5) 60 (35.5) 22 (31.9) 16 (22.5)
Same or less 40 (50.0) 53 (59.6) 93 (55.0) 43 (62.3) 46 (64.8)
Total 80 (100) 89 (100) 169 (100) 69 (100) 71 (100)
Able to understand
your illness
Much better 8 (10.8) 14 (15.9) 22 (13.6) 0.662 4 (6.3) 9 (13.0)
Better 30 (40.5) 31 (35.2) 61 (37.7) 22 (34.4) 20 (29.0)
Same or less 36 (48.6) 43 (48.9) 79 (48.8) 38 (59.4) 40 (58.0)
Total 74 (100) 88 (100) 162 (100) 64 (100) 69 (100)
Able to cope with
your illness
Much better 6 (7.8) 9 (10.0) 15 (9.0) 0.835 2 (3.0) 7 (10.1)
Better 30 (39.0) 33 (36.7) 63 (37.7) 26 (38.8) 17 (24.6)
Same or less 41 (53.2) 48 (53.3) 89 (53.3) 39 (58.2) 45 (65.2)
Total 77 (100) 90 (100) 167 (100) 67 (100) 69 (100)
Able to keep yourself
healthy
Much better 5 (7.1) 6 (7.1) 11 (7.1) 0.721 3 (4.8) 9 (14.1)
Better 23 (32.9) 25 (29.4) 48 (31.0) 21 (33.3) 10 (15.6)
Same or less 42 (60.0) 54 (63.5) 96 (61.9) 39 (61.9) 45 (70.3)
Total 70 (100) 85 (100) 155 (100) 63 (100) 64 (100)
Confident about
your health
Much more 2 (2.7) 3 (3.4) 5 (3.1) 0.687 3 (4.5) 5 (7.0)
More 19 (25.7) 24 (27.6) 43 (26.7) 12 (18.2) 14 (19.7)
Same or less 53 (71.6) 60 (69.0) 113 (70.2) 51 (77.3) 52 (73.2)
Total 74 (100) 87 (100) 161 (100) 66 (100) 71 (100)
Able to help yourself Much more 7 (9.6) 8 (9.2) 15 (9.4) 0.365 3 (4.5) 5 (6.9)
More 24 (32.9) 21 (24.1) 58 (66.7) 20 (30.3) 11 (15.3)
Same or less 42 (57.5) 58 (66.7) 100 (62.5) 43 (65.2) 56 (77.8)
Total 73 (100) 87 (100) 160 (100) 66 (100) 72 (100)
594 Vol. 50 No. 5 November 2015Ahmed et al.(26.5% response rate), 182 patients completed baseline
questionnaires, 152 completed the two-week question-
naires, 126 completed the questionnaires at four weeks,
and 120 completed the six-week questionnaires. The
critical point in the analysis was the two-week point,
the point at which patients in Group A (intervention
arm) had already received the SPARC intervention
and patients in Group B (control arm) had not yet
received the SPARC intervention. Seven patients did
not complete the trial, citing questionnaire completion
and taking part in the trial too burdensome as reasons
for not continuing. Two patients expressed concern
around issues of data collection and had anticipated
more face-to-face contact visits as opposed to receiving
postal questionnaires. At the end of the trial (eight
weeks after completion of baseline questionnaires),
23 patients had died and 159 patients were alive. There
was no significant difference in the number of deaths
between the intervention and control groups. In Group
A (intervention), nine people (10.3%) and in Group B
(control), 14 people (14.7%) died within the eight-
week study period. A summary of the recruitment is
presented in Fig. 1.
Baseline Data
Of the 182 study participants, 84 were males
(46.2%) and 98 were females (53.8%). The mean
age of the participants on trial registration was64.47 years (median 66.00 years; SD 12.57; minimum
age 27 years; and maximum age 90 years). There
were 87 (47.8%) participants in the intervention arm
(Group A) and 95 (52.2%) participants in the control
arm (Group B); there was no significant difference in
the partnership status of patients in Group A vs.
Group B. Most patients were married (n ¼ 118;
64.8%) and of White-British ethnicity (n ¼ 173;
95.1%). No significant differences were observed be-
tween the intervention and control groups with
respect to age distribution, gender distribution, in
the baseline scores for MYCAW, EQ-5D, and PEI, or
in any other study parameters. Demographic charac-
teristics of participants are summarized in Table 3.
MYCAW: Comparison of Groups From Baseline to
Weeks 2, 4, and 6
The mean MYCAW Concern 1 score for both groups
improved over six weeks (Table 4). The overall mean
change in score from baseline toWeek 2 was 0.368 (me-
dian 0; SD 1.39); frombaseline toWeek 4was 0.430 (me-
dian 0; SD 1.66); and from baseline toWeek 6 was 0.462
(median 0; SD 1.59). There were no significant differ-
ences (no detectable effect) between the control and
intervention groups in the change in mean MYCAW 1
scores at two-, four-, or six-week follow-up.
There was, however, a significant difference in the
rankings for the change in MYCAW Concern 1 score
Week 2 Week 4 Week 6
Total P
Group A
(Intervention)
Group B
(Control) Total P
Group A
(Intervention)
Group B
(Control) Total P
13 (9.3) 0.693 1 (1.9) 1 (1.8) 2 (1.8) 0.781 2 (3.8) 6 (10.3) 8 (7.3) 0.607
38 (27.1) 19 (35.8) 19 (33.3) 38 (34.5) 17 (32.7) 15 (25.9) 32 (29.1)
89 (63.6) 33 (62.3) 37 (64.9) 70 (63.6) 33 (63.5) 37 (63.8) 70 (63.6)
140 (100) 53 (100) 57 (100) 110 (100) 52 (100) 58 (100) 110 (100)
13 (13.8) 0.481 2 (3.8) 4 (7.1) 6 (5.5) 0.676 4 (8.0) 6 (10.3) 10 (9.3) 0.346
42 (31.6) 19 (35.8) 19 (33.9) 38 (34.9) 11 (22.0) 17 (29.3) 28 (25.9)
78 (58.6) 32 (60.4) 33 (58.9) 65 (59.6) 35 (70.0) 35 (60.3) 70 (64.8)
133 (100) 53 (100) 56 (100) 109 (100) 50 (100) 58 (100) 109 (100)
9 (6.6) 0.989 1 (1.9) 3 (5.1) 4 (3.6) 0.995 3 (5.9) 5 (8.5) 8 (7.3) 0.884
43 (31.6) 16 (30.2) 14 (23.7) 30 (26.8) 13 (25.5) 13 (22.0) 26 (23.6)
84 (61.8) 36 (67.9) 42 (71.2) 78 (69.6) 35 (68.6) 41 (69.5) 76 (69.1)
136 (100) 53 (100) 59 (100) 112 (100) 51 (100) 59 (100) 110 (100)
12 (9.4) 0.939 2 (3.8) 3 (5.6) 5 (4.7) 0.948 2 (4.1) 5 (8.9) 7 (6.7) 0.446
31 (24.4) 12 (23.1) 11 (20.4) 23 (21.7) 10 (20.4) 11 (19.6) 21 (20)
84 (66.1) 38 (73.1) 40 (74.1) 78 (73.6) 37 (75.5) 40 (71.4) 77 (73.3)
127 (100) 52 (100) 54 (100) 106 (100) 49 (100) 56 (100) 105 (100)
8 (5.8) 0.507 1 (2.0) 1 (1.7) 2 (1.8) 0.445 2 (4.0) 3 (5.2) 5 (4.6) 0.319
26 (19.0) 9 (17.6) 7 (11.9) 16 (14.5) 4 (8.0) 9 (15.5) 13 (12.0)
103 (75.2) 41 (80.4) 51 (86.4) 92 (83.6) 44 (88.0) 46 (79.3) 90 (83.3)
137 (100) 51 (100) 59 (100) 110 (100) 50 (100) 58 (100) 108 (100)
8 (5.8) 0.305 4 (7.0) 0 (0) 4 (3.6) 0.088 3 (6.3) 3 (5.2) 6 (5.7) 0.625
31 (22.5) 8 (15.1) 8 (14.0) 16 (14.5) 9 (18.8) 9 (15.5) 18 (17.0)
99 (71.7) 41 (77.4) 49 (86.0) 90 (81.8) 36 (75.0) 46 (79.3) 82 (77.4)
138 (100) 53 (100) 57 (100) 110 (100) 48 (100) 58 (100) 106 (100)
Table 6
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tion: mean rank of patients: 61.21) and Group B (con-
trol: mean rank of patients: 75.37) (Mann-Whitney
Z ¼ 2.192; P ¼ 0.028; n ¼ 136). Overall, patients in
Group B (control) showed greater improvement or
less deterioration in the MYCAW score than patients
in Group A (intervention). The mean change in MY-
CAW Concern 1 score (baseline to Week 2) in Group
A (intervention) was 0.15 (SD 1.32; median 0) (a small
improvement) vs. Group B (control) 0.57 (SD 1.44; me-
dian 0). When the scores for changes in MYCAW
Concern 1 score for the patients were recoded (base-
line to Week 2) into groups for deterioration/no
change/improvement, there was a statistically signifi-
cant association between the change in MYCAW
Concern 1 score and study arm (c2trend ¼ 5.51; degrees
of freedom ¼ 1; P ¼ 0.019). A higher proportion of pa-
tients in Group B (control: 34 of 70 [48.6%]) had an
improvement in the MYCAW Concern 1 score (baseline
to Week 2) compared with patients in Group A (inter-
vention: 19 of 66 [28.8%]). A higher proportion of
patients in Group A (intervention: 16 of 66; 24.2%)
showed a deterioration in the MYCAW Concern 1 score
(baseline to Week 2) compared with patients in Group
B (control: 10 of 70; 14.3%). There was no significant
difference in the rankings for the change in MYCAW
Concern 1 score from baseline to Week 4 or from base-
line to Week 6.MYCAW Concerns at Baseline
Of the 182 patients completing baseline question-
naires, 173 (95.1%) respondents nominated and scored
a primary concern and 125 (68.7%) nominated and
scored a secondary concern. For both MYCAW primary
and secondary concerns, physical symptoms, condition
and disability predominated, but other concerns, such
as apprehension for themselves or others, concerns
about disease progression and dying, feelings of loss of
function or purpose, and about help needed, also were
prominent. Similarities were marked, in that for all
groups, symptoms, condition, and disability featured
most strongly. For cancer survivors, and those receiving
end-of-life cancer care, all concerns were named: appre-
hension for themselves orothers; concerns related to the
progressionofdisease; psychological concerns; concerns
related to loss or existential issues; concerns about
needinghelp; theeffecton their social life;workorfinan-
cial issues; and treatment effects.EQ-5D Variables: Comparison of Groups From
Baseline to Weeks 2, 4, and 6
There were no meaningful or significant associa-
tions between any of the EQ-5D domains for Groups
A (intervention) and B (control) at baseline, Weeks
2, 4, or 6. Table 5 shows the frequency of responses
for the EQ-5D domains at all of the time points. It is
596 Vol. 50 No. 5 November 2015Ahmed et al.also worth noting that, in this analysis, the mean EQ-
5D scores did not change in any significant or mean-
ingful way.
PEI Scores: Comparison of Groups From Baseline to
Weeks 2, 4, and 6
Table 6 shows the distribution of responses for the
PEI questions at baseline and Weeks 2, 4, and 6,
respectively, in Groups A (intervention) and B (con-
trol) and in the total sample (Aþ B). There were no
meaningful or significant associations between the
PEI responses to the questions for either group or in
the total sample at any of the time points.Discussion
The unexpected negative finding that a higher pro-
portion of patients in the control group (34 of 70;
48.6%) showed an improvement in their MYCAW score
from baseline to Week 2 compared with the interven-
tion group (19 of 66; 28.8%) (P ¼ 0.019) raises ques-
tions about the application of SPARC and possibly
other holistic needs assessment questionnaires in the
context of a specialist palliative care service.
No positive effect of the intervention on either the
primary or secondary outcome measures was observed
at two, four, or six weeks, suggesting that the interven-
tion did not have a detectable beneficial effect at any
point and the difference between arms was obliterated
when the control arm received SPARC.
Data that indicate that most patients felt that no
particular action or benefit followed from completion
of the SPARC will be reported elsewhere. There were
no meaningful or significant differences between the
control and intervention groups in the scores for
health-related quality of life as recorded in the general
measure EQ-5D. This measure did not significantly
change over the six weeks, as would be expected of pa-
tients attending a palliative care service. However, in
contrast, there appears to be improvement in the
most important concern as recorded in the MYCAW;
this suggests that usual palliative care is having a bene-
ficial effect in this respect.
Results in the Context of Other Studies
Several other studies have examined the clinical
utility of some holistic needs assessment tools. These
tools include 1) Palliative Care Assessment Tool,35,36
2) the Initial Health Assessment,37 and 3) Needs at
the End of Life Screening Tool.38 Although the
studies have measured changes in clinical outcomes
after needs assessment, no controlled study has
demonstrated an improvement in clinical or patient-
reported outcomes as a result of the intervention.
Although many of these studies demonstrated animprovement in documentation of needs, uptake of
findings and action after the assessment of needs
have been described as poor, with no significant over-
all improvements in care outcomes. The reasons for
these results are unclear but could be a result of inad-
equate power to detect a change; the tools not being
comprehensive enough for holistic needs assessments;
outcomes chosen may have been inappropriate;
HCPs’ attitudes, knowledge, or skills; and timing of
and the availability/nonavailability of services.38 It is
also possible that standardized needs assessments will
never supplement the quality of care unless properly
integrated with the clinical methods and routine
care planning procedures of the clinical team. Scan-
drett et al.38 proposed that new methods to achieve
practice change should be considered and evaluated
when assessing such interventions.7
Limitations of the Study
Our poor recruitment of patients within the hospi-
tal support service meant our study sample had fewer
patients with conditions other than cancer and a
smaller proportion of patients acutely ill than the
whole population of patients referred to the palliative
care service.
The context of a specialist palliative care service is
possibly the most difficult environment to test an
assessment intervention in that the existing holistic
needs assessments may be sufficient to detect all is-
sues that require attention. The SPARC pilot trial
focused primarily on outcomes, not on the processes
involved in implementing the intervention. The Med-
ical Research Council framework requires an evalua-
tion of the pilot study, and a process evaluation is
underway and will be reported elsewhere, to eluci-
date the precise mechanism by which this result
came about.Conclusions
This trial result identifies a potential negative effect
of SPARC in specialist palliative care services, raising
questions that standardized holistic needs assessment
questionnaires may be counterproductive if not inte-
grated with a clinical assessment that informs the
care plan. It may raise expectations that are not subse-
quently met.
We can, however, conclude that a larger trial with
more power to detect an effect is highly unlikely to
be positive. A larger trial in specialist outpatient or
home care services using the same design and
outcome measures is unlikely to demonstrate any
benefit. It is nevertheless possible that SPARC has
utility for the original purpose for which it was de-
signed, as a screening tool, in primary care or general
Vol. 50 No. 5 November 2015 597Palliative Care Holistic Needs Assessment RCTmedical care for selection of patients who may
benefit from a referral to specialist palliative care. It
is also possible that, were SPARC to be included in
the routine clinical assessment that informs a care
plan within a specialist service, then immediate
benefit might follow within an effective supportive
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